Navigation Links
PersonalDiets Announces New Plan-A-Meal Tools to Help With New Year's Weight Loss Resolutions!
Date:12/31/2008

PLACERVILLE, Calif., Dec. 31 /PRNewswire/ -- Designed to help dieters stick to their New Year's resolution of losing weight, PersonalDiets today unveiled a new version of Plan-a-Meal software that is iPhone and BlackBerry friendly.

Users can now easily customize their meal plans throughout the day using their own high-tech gadgets. With a few keystrokes, dieters can quickly include restaurant and take-out meals, grocery-bought convenience foods and home-prepared recipes to suit their tastes, while keeping their diets on track.

The big difference between other online diet programs and PersonalDiets is that the exclusive Plan-a-Meal tool allows dieters to quickly change their food choices as their own day changes, using customized drop down menus and client-side technology.

This makes weight loss less boring, more personal and more flexible. The speed and ease of use sets PersonalDiets apart from slower loading, cumbersome databases used by other diet companies and meets the demands of today's tech- savvy online clients who want quick and easy answers.

"Weight loss research show that an easy-to-stick-with diet works best, said Craig Kohn, PersonalDiets Director." "It's why PersonalDiets has achieved an 85% success rate. Plan-a-Meal software lets dieters make changes at will while maintaining a healthy balance of good foods so that they reach their weight and health goals."

The added benefit of PersonalDiets comes from the ability to interchange foods based on tastes, preferences and lifestyle. With a click of a mouse food choices are easily replaced, yet daily meal plans automatically adjust to help keep dieters on track.

"It's a more practical and more useful diet plan," said Kohn. "Our Plan-a- Meal database continues to expand as unique and common foods available worldwide are added daily. Dieters don't have to count calories, they just input their
'/>"/>

SOURCE PersonalDiets
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
2. China Medical Technologies Announces the Completion of the Sale of its HIFU Business
3. American Scientific Resources Announces Addition of New Board Members
4. Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits
5. Versus Technology Announces Fiscal Year Results
6. Perrigo Announces FDA Final Approval for Ibuprofen PM
7. Ocean Spray(R) Announces Sugar-Free Drink Mixes - A Sweet Way for Dieters to Stick to Their Resolutions
8. Prime Companies Announces Launch of New Dental Web Site
9. Californian Files Contact Lens Solution False Advertising Class Action Against Advanced Medical Optics, Announces the Schmidt Firm, LLP
10. The Womens Heart Health Initiative announces creation of new womens cardiology research fellowship
11. Accurate Background Announces Selection from Right at Home Background Screening Services Offered to Right at Home's National Network of Offices
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 1NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 2NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 3NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 4SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 1SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 2SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 3SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 4Terumo Cardiovascular Systems Initiates U S Clinical Trial for Anaconda 28TM 29 AAA Stent Graft System 4777 1Terumo Cardiovascular Systems Initiates U S Clinical Trial for Anaconda 28TM 29 AAA Stent Graft System 4777 2